Esperion to buy Corstasis in $255M deal for nasal diuretic
Compartilhar
Esperion Therapeutics (NASDAQ:ESPR) moved to significantly broaden its cardiovascular portfolio on Tuesday, announcing a deal to acquire privately held Corstasis Therapeutics and its first-of-its-kind nasal spray for heart failure-related edema.
